Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The high-affinity IgE receptor: lessons from structural analysis].

Ulrich Blank1, Marie-Hélène Jouvin, Claudine Guérin-Marchand

  • 1Institut Pasteur, Unité d'Immuno-Allergie, 25, rue du Docteur Roux, 75724 Paris, France. ublank@pasteur.fr

Medecine Sciences : M/S
|July 3, 2003
PubMed
Summary

New research targets the IgE receptor (FcERI) central to allergic reactions. A novel antibody and potential small molecules aim to block IgE binding, offering new therapeutic avenues for allergies like asthma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Basophils drive the resolution and promote wound healing in adult and aged mice.

The Journal of experimental medicine·2026
Same author

Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet. Haematology·2026
Same author

Assessing Patient-Reported Outcomes in Acute Attacks of Hereditary Angioedema: Insights from a Mixed Methods Study of Participants Receiving Standard-of-Care Treatments in a Real-World Setting.

Clinical reviews in allergy & immunology·2026
Same author

A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study.

Journal of neuromuscular diseases·2026
Same author

Complex mast cell CCL2-chemokine trafficking patterns during local allergic responses.

The Journal of allergy and clinical immunology·2026
Same author

Isoquercetin and Zafirlukast Cooperatively Suppress Tumor Growth and Thromboinflammatory Signaling in a Xenograft Model of Ovarian Cancer.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2025

Area of Science:

  • Immunology
  • Allergology
  • Pharmacology

Background:

  • The high-affinity IgE receptor (FcERI) on mast cells and basophils drives allergic reactions.
  • Allergic disease prevalence is increasing, necessitating novel therapeutic strategies.
  • Current treatments focus on blocking IgE-mediated mast cell activation.

Purpose of the Study:

  • To explore new therapeutic targets for allergic diseases.
  • To investigate the potential of blocking IgE-FcERI interactions.
  • To leverage structural insights for drug design.

Main Methods:

  • Development of a humanized antibody targeting free IgE.
  • Analysis of the IgE-FcERI complex structure.
  • Design of small chemical inhibitors.

Related Experiment Videos

Main Results:

  • A humanized antibody effectively targets free IgE, preventing FcERI-mediated cell activation.
  • The antibody shows efficacy in clinical trials for asthma and allergic rhinitis.
  • Structural elucidation of IgE-FcERI complex provides a basis for novel inhibitor design.

Conclusions:

  • Targeting the IgE-FcERI interaction is a promising strategy for allergic disease treatment.
  • Engineered antibodies offer a viable therapeutic option.
  • Structural biology advances enable the rational design of small molecule inhibitors for FcERI.